{"id":557846,"date":"2025-09-22T14:51:26","date_gmt":"2025-09-22T14:51:26","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/557846\/relapsedrefractory-myelodysplastic-syndrome-pipeline-2025-pioneering-clinical-developments-by-more-than-five-global-companies-delveinsight-highlighting-cantex-pharmaceuticals-novartis-newave-p.html"},"modified":"2025-09-22T14:51:26","modified_gmt":"2025-09-22T14:51:26","slug":"relapsedrefractory-myelodysplastic-syndrome-pipeline-2025-pioneering-clinical-developments-by-more-than-five-global-companies-delveinsight-highlighting-cantex-pharmaceuticals-novartis-newave-p","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/557846\/relapsedrefractory-myelodysplastic-syndrome-pipeline-2025-pioneering-clinical-developments-by-more-than-five-global-companies-delveinsight-highlighting-cantex-pharmaceuticals-novartis-newave-p.html","title":{"rendered":"Relapsed\/Refractory Myelodysplastic Syndrome Pipeline 2025: Pioneering Clinical Developments by More Than Five Global Companies \u2013 DelveInsight | Highlighting Cantex Pharmaceuticals, Novartis, Newave P"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\">\n<div><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1758517726.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Relapsed\/Refractory Myelodysplastic Syndrome Pipeline 2025: Pioneering Clinical Developments by More Than Five Global Companies &ndash; DelveInsight | Highlighting Cantex Pharmaceuticals, Novartis, Newave P\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1758517726.jpg\" alt=\"Relapsed\/Refractory Myelodysplastic Syndrome Pipeline 2025: Pioneering Clinical Developments by More Than Five Global Companies &ndash; DelveInsight | Highlighting Cantex Pharmaceuticals, Novartis, Newave P\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px;border:0 solid !important\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Relapsed\/Refractory Myelodysplastic Syndrome Pipeline Analysis<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic;padding:8px 0px\">DelveInsight\u2019s, \u201cRelapsed or Refractory Myelodysplastic Syndrome &#8211; Pipeline Insight, 2025,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.<\/div>\n<p style=\"text-align: justify\">As relapsed or refractory myelodysplastic syndrome (r\/r MDS) continues to grow globally and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is an increasing need for safer and more effective treatments. According to DelveInsight, the r\/r MDS pipeline includes more than five pharmaceutical and biotech companies developing over five therapeutic candidates, spanning various stages of clinical and preclinical development. This highlights the robust innovation and dedication to tackling this critical public health challenge.<\/p>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s report, &ldquo;Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight 2025,&rdquo; offers a comprehensive and strategic review of the R&amp;D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving r\/r MDS therapeutics market and the breakthroughs shaping its future.<\/p>\n<p style=\"text-align: justify\"><strong>Explore the Cutting-Edge Landscape of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Relapsed or Refractory Myelodysplastic Syndrome Drug Development<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">DelveInsight&rsquo;s report on the relapsed or refractory myelodysplastic syndrome (r\/r MDS) pipeline highlights a dynamic landscape with over five active companies developing more than five therapeutic candidates for r\/r MDS treatment.<\/p>\n<\/li>\n<li>\n<p>On October 24, 2023, the FDA approved ivosidenib (Tibsovo) for adult patients with r\/r MDS carrying an IDH1 mutation. This approval was based on the AG120-C-001 trial, an open-label, single-arm, multicenter study with 18 adult participants, all receiving oral ivosidenib daily in 28-day cycles. The study reported complete responses in all patients.<\/p>\n<\/li>\n<li>\n<p>Leading companies such as Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others are actively developing new therapies to enhance the r\/r MDS treatment landscape. Promising pipeline candidates include CX-01, LP-108, BTX-A51, among others, which are at various stages of development.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Overview:<\/strong><\/p>\n<p style=\"text-align: justify\">Myelodysplastic syndromes (MDS) are disorders marked by impaired blood cell production, resulting in cytopenias and genetic instability, which can eventually progress to acute myeloid leukemia (AML). Patients with MDS often experience significant clinical symptoms and face a higher risk of mortality due to both cytopenias and AML transformation. The main goals of MDS treatment are to relieve symptoms, slow disease progression, and improve survival and quality of life. Some individuals may remain symptom-free, with MDS discovered incidentally during routine blood tests. Treatment approaches for MDS include supportive care, pharmacologic therapies, and hematopoietic stem cell transplantation.<\/p>\n<p style=\"text-align: justify\"><strong>Download the Relapsed or Refractory Myelodysplastic Syndrome sample report to know in detail about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Relapsed or Refractory Myelodysplastic Syndrome treatment market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify\">The Relapsed or Refractory Myelodysplastic Syndrome pipeline insights report 2025, provides insights into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Provides comprehensive insights into key companies developing therapies in the Relapsed or Refractory Myelodysplastic Syndrome Market.<\/p>\n<\/li>\n<li>\n<p>Categorizes Relapsed or Refractory Myelodysplastic Syndrome therapeutic companies by development stage: early, mid, and late-stage.<\/p>\n<\/li>\n<li>\n<p>Highlights major companies involved in targeted therapy development, including both active and inactive (paused\/discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Reviews emerging Relapsed or Refractory Myelodysplastic Syndrome drugs under development based on:<\/p>\n<ul>\n<li>\n<p>Stage of development<\/p>\n<\/li>\n<li>\n<p>Relapsed or Refractory Myelodysplastic Syndrome Route of administration<\/p>\n<\/li>\n<li>\n<p>Target receptor<\/p>\n<\/li>\n<li>\n<p>Monotherapy vs. combination therapy<\/p>\n<\/li>\n<li>\n<p>Relapsed or Refractory Myelodysplastic Syndrome Mechanism of action<\/p>\n<\/li>\n<li>\n<p>Molecular type<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Offers detailed analysis of:<\/p>\n<ul>\n<li>\n<p>Company-to-company and company-academia collaborations<\/p>\n<\/li>\n<li>\n<p>Relapsed or Refractory Myelodysplastic Syndrome Licensing agreements<\/p>\n<\/li>\n<li>\n<p>Funding and investment activities supporting future Relapsed or Refractory Myelodysplastic Syndrome market advancement.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Unlock key insights into emerging Relapsed or Refractory Myelodysplastic Syndrome therapies and market strategies here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>CX-01: Cantex Pharmaceuticals<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">CX-01 is a novel agent derived from unfractionated heparin with minimal anticoagulant activity. It interferes with critical protein pathways that enable AML cells to migrate to and persist in the bone marrow, where they are protected from chemotherapy. CX-01 also targets proteins associated with chemotherapy resistance and delayed platelet recovery, increasing AML cells&rsquo; sensitivity to treatment and potentially improving patient outcomes. These mechanisms make CX-01 a promising therapy for myelodysplastic syndrome, multiple myeloma, and lymphomas. It is currently being tested in Phase 2 clinical trials for Myelodysplastic Syndrome.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>LP-108: Newave Pharmaceuticals<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">This drug acts as an inhibitor of the proto-oncogene protein c-bcl-2 and is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed or refractory Myelodysplastic Syndrome.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>BTX-A51: BioTheryX<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">BTX-A51 is thought to target CK1-alpha in leukemic stem cells, as well as super-enhancer-associated proteins CDK7 and CDK9, thereby inhibiting the transcription of key genes that drive cancer growth. Preclinical studies in animal models have demonstrated promising outcomes, indicating that BTX-A51 may effectively eradicate AML stem cells and could have potential applications in multiple cancer types. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of Myelodysplastic Syndrome.<\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Assessment by Product Type<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Mono<\/p>\n<p style=\"text-align: justify\">&bull; Combination<\/p>\n<p style=\"text-align: justify\">&bull; Mono\/Combination<\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome By Stage<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify\">&bull; Early-stage product (Phase I) along with the details of<\/p>\n<p style=\"text-align: justify\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Assessment by Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Oral<\/p>\n<p style=\"text-align: justify\">&bull; Parenteral<\/p>\n<p style=\"text-align: justify\">&bull; Intravenous<\/p>\n<p style=\"text-align: justify\">&bull; Subcutaneous<\/p>\n<p style=\"text-align: justify\">&bull; Topical<\/p>\n<p style=\"text-align: justify\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Assessment by Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Recombinant fusion proteins<\/p>\n<p style=\"text-align: justify\">&bull; Small molecule<\/p>\n<p style=\"text-align: justify\">&bull; Monoclonal antibody<\/p>\n<p style=\"text-align: justify\">&bull; Peptide<\/p>\n<p style=\"text-align: justify\">&bull; Polymer<\/p>\n<p style=\"text-align: justify\">&bull; Gene therapy<\/p>\n<p style=\"text-align: justify\"><strong>Download sample pages to get an in-depth assessment of the emerging Relapsed or Refractory Myelodysplastic Syndrome therapies and key <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Relapsed or Refractory Myelodysplastic Syndrome companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify\">1. Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary<\/p>\n<p style=\"text-align: justify\">3. Relapsed or Refractory Myelodysplastic Syndrome Current Treatment Patterns<\/p>\n<p style=\"text-align: justify\">4. Relapsed or Refractory Myelodysplastic Syndrome &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify\">6. Relapsed or Refractory Myelodysplastic Syndrome Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify\">7. Relapsed or Refractory Myelodysplastic Syndrome Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify\">10. Inactive Products<\/p>\n<p style=\"text-align: justify\">11. Dormant Products<\/p>\n<p style=\"text-align: justify\">12. Relapsed or Refractory Myelodysplastic Syndrome Discontinued Products<\/p>\n<p style=\"text-align: justify\">13. Relapsed or Refractory Myelodysplastic Syndrome Product Profiles<\/p>\n<p style=\"text-align: justify\">14. Relapsed or Refractory Myelodysplastic Syndrome Key Companies<\/p>\n<p style=\"text-align: justify\">15. Relapsed or Refractory Myelodysplastic Syndrome Key Products<\/p>\n<p style=\"text-align: justify\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify\">17. Relapsed or Refractory Myelodysplastic Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify\">18. Relapsed or Refractory Myelodysplastic Syndrome Future Perspectives<\/p>\n<p style=\"text-align: justify\">19. Relapsed or Refractory Myelodysplastic Syndrome Analyst Review<\/p>\n<p style=\"text-align: justify\">20. Appendix<\/p>\n<p style=\"text-align: justify\">21. Report Methodology<\/p>\n<p style=\"text-align: justify\"><strong>Request the sample PDF to get detailed insights about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Relapsed or Refractory Myelodysplastic Syndrome pipeline reports offerings<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=relapsedrefractory-myelodysplastic-syndrome-pipeline-2025-pioneering-clinical-developments-by-more-than-five-global-companies-delveinsight-highlighting-cantex-pharmaceuticals-novartis-newave-p\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=relapsedrefractory-myelodysplastic-syndrome-pipeline-2025-pioneering-clinical-developments-by-more-than-five-global-companies-delveinsight-highlighting-cantex-pharmaceuticals-novartis-newave-p\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Relapsed\/Refractory Myelodysplastic Syndrome Pipeline Analysis DelveInsight\u2019s, \u201cRelapsed or Refractory Myelodysplastic Syndrome &#8211; Pipeline Insight, 2025,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/557846"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=557846"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/557846\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=557846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=557846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=557846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}